drugset
drugset / Trial / NCT00509769

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT00509769 ↗

Phase 2 Completed 112 enrolled Genentech, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).

Timeline

Start
2007-07
Primary completion
2009-01
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab emtansine Other / unclassified 3.6 mg/kg Intravenous

Indications

breast cancer